Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY:DGX)

179.33 -0.30 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins. 
Via Benzinga
Earnings Preview: Quest Diagnostics
Via Benzinga
Looking Into Quest Diagnostics's Recent Short Interest
Via Benzinga
Decoding 7 Analyst Evaluations For Quest Diagnostics
Via Benzinga
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
Via Benzinga
Uncovering Dividend Opportunities with NYSE:DGX.
Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. 
Via Chartmill
5 Analysts Assess Quest Diagnostics: What You Need To Know
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... 
Via Benzinga
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue... 
Via Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc. 
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist
The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tuesday. The apprehensions reflect uncertainties regarding geopolitics,... 
Via Benzinga
Topics Artificial Intelligence
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
The Analyst Landscape: 5 Takes On Quest Diagnostics
Via Benzinga
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... 
Via Benzinga
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Topics Stocks
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered samples out of 5.5 million in 2023. The rise in synthetic urine use and... 
Via Benzinga
Topics Cannabis
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. 
Via Talk Markets
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth. 
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.